Methods and compositions for suppressing bovine leukemia...

Details Methods and compositions for suppressing bovine leukemia... Methods and compositions for suppressing bovine leukemia...

2000-07-13

2003-04-01

Housel, James (Department: 1642)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S236100, C514S002600

Reexamination Certificate

active

06541013

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to methods and compositions for suppressing bovine leukemia virus-related lymphocyte proliferation using a Shiga-toxin polypeptide.
REFERENCES
Full citations for the publications referenced herein are found at the end of the specification immediately preceding the claims. The disclosures of these references and cited patent documents are incorporated herein by reference in their entirety.
ABBREVIATIONS
Abbreviations used are as follows:
BLV
bovine leukemia virus
PL
persistent lymphocytosis
SLP
spontaneous lymphocyte proliferation
PBMC
peripheral blood mononuclear cells
Stx1
Shiga-toxin type 1 holotoxin
Stx1 A
Shiga-toxin type 1 subunit A
Stx1 B
Shiga-toxin type 1 subunit B
BACKGROUND OF THE INVENTION
Bovine Leukemia Virus (BLV) is an oncogenic retrovirus responsible for the erizootic form of bovine lymphosarcoma, the most frequent malignancy of domestic cattle (Ferrer 1980). BLV infection results in a 1-8 year long asymptomatic period (Ferrer et al. 1979), followed by development of persistent lymphocytosis (PL) in approximately 30% of infected cattle with progression to a malignant lymphosarcoma in fewer than 10% of the animals (Ferrer et al. 1979). The PL stage is a benign neoplasia of B lymphocytes, which are the predominant or exclusive targets of BLV (Esteban et al. 1985). This stage of infection is associated with an increased percentage of peripheral B lymphocytes containing provirus as well as increased viral gene expression (Mirsky et al. 1996). The development of PL markedly enhances the probability of transmission (Mammerickx et al. 1987). The critical importance of PL to transmission of this blood-borne disease was demonstrated by experiments showing that it required significantly less blood from cattle with persistent lymphocytosis to transmit BLV than blood from infected cattle which did not have persistent lymphocytosis (Mammerickx et al. 1987). Moreover, vertical transmission from BLV-infected dams to their calves has been shown to be strongly correlated with persistent lymphocytosis (Agresti et al. 1993).
In cattle, the ability to transmit BLV varies (Weber et al. 1983; Mammerickx et al. 1987), and expression of antigen after in vitro culture has been shown to correlate with infectivity (Miller et al. 1985). The level of BLV expression in the animal also may correlate with the probability of development of persistent lymphocytosis (Cockerell et al. 1988; Dropulic et al. 1992). Moreover, persistent lymphocytosis is a strong risk factor for development of lymphoma. In 1-10% of the animals with persistent lymphocytosis, B cell clones undergo neoplastic transformation, leading to leukemia or lymphoma (Ferrer et al. 1979), and cattle with persistent lymphocytosis are three times more likely to develop lymphoma than infected cattle without persistent lymphocytosis (Ferrer et al. 1979).
BLV is prevalent in dairy operations, with up to 89% of the U.S. dairy operation seropositive for BLV (Howie 1997). Not only does the virus kill cattle, milk and fat yields in BLV-infected cows with persistent lymphocytosis are greatly reduced (Da et al., 1993). Moreover, BLV also produces malignant lymphomas in sheep (Wittman et al. 1989). However, the greatest economic impact of BLV infection in the United States arises from the fact that several countries will not import cattle from BLV-infested areas. Although various attempts have been made to develop a vaccine against BLV infection, an effective vaccine to protect cattle or sheep is not available (Miller et al. 1978; Theilen 1982). BLV infection is thus a costly impediment to cattle production.
Peripheral blood mononuclear cells (PBMC) from BLV-infected cattle proliferate spontaneously in vitro (Takashima & Olson 1981; Thorn et al. 1981). This spontaneous lymphocyte proliferation (SLP) is particularly vigorous in PBMC cultures from cattle in the PL stage of infection. Derepression of viral gene transcription and the synthesis of viral proteins precede SLP (Kettmann et al. 1976; Baliga & Ferrer 1977; Ferrer 1980). Therefore, SLP provides a tractable model system for identifying factors that are capable of preventing BLV-induced neoplasia and malignant lymphoma in infected cattle. The present invention shows that Shiga toxin type 1 (Stx1) is a potent and selective inhibitor of BLV-induced SLP.
Stx1 belongs to a large family of ribosome-inactivating proteins (RIPs) that are found in a variety of higher plants and some bacteria. Class 1 RIPs are N-glycosidases that inactivate ribosomes by removing a single adenine in a specific ribosomal RNA sequence (Endo et al. 1987; Igarishi et al. 1987; Endo et al. 1988). Class 2 RIPs are composed of an A subunit homologous to class 1 RIPs, noncovalently joined to one or more B subunits, usually galactose-specific lectins, that facilitate toxin binding and uptake into target cells. Stx1 is a class 2 RIP composed of an A subunit associated with a pentamer of receptor-binding B subunits. Because of their ability to bind to target cells, class 2 RIPs are potent cytotoxins. Stx1 is toxic to cells that express high levels of the toxin receptor, globotriosylceramide (Gb3 or CD77), most notably Vero cells and human glomerular endothelial cells (Jackson 1990).
Plant RIPs of both class 1 (e.g., pokeweed antiviral protein, titrin, trichosanthin) and class 2 (e.g., ricin) have potent antiviral activities (Stirpe et al. 1992). These compounds often inhibit viral proliferation in mammalian cells in vitro, and some have been tested in vivo in clinical or laboratory settings. For example, ricin can eliminate latent herpes simplex virus in mice (Hino et al. 1988). Other plant RIPs inhibited replication of human immunodeficiency virus type 1 (HIV1) in human peripheral blood mononuclear cells at concentrations nontoxic to uninfected cells (Olson et al. 1991; Lee-Huang et al. 1995).
One problem associated with using RIPs as general antiviral agents is their specificity (Wachinger et al. 1993; Watanabe et al. 1997). For example, the RIP Bryodin selectively inhibits the growth of HIV-1-infected cells, whereas RIPs gelonin and ricin did not (Wachinger et al. 1993). Another concern is that RIPs are highly cytotoxic (Benigni et al. 1995; Sparapani et al. 1997; Yoshida et al. 1999). Therefore, although the antiviral effects of some RIPs are known, the use of RIPs as antiviral agents has not been generally applicable. Surprisingly, it has been discovered that Stx1 strongly inhibits BLV-related cell proliferation and BLV expression. Specifically, this activity is manifested by subunit A of Stx1, which is nontoxic to ruminants or humans.
SUMMARY OF THE INVENTION
The present invention provides methods and compositions for suppressing BLV-related lymphocyte proliferation. The method utilizes a composition that provides a Shiga-toxin polypeptide having antiviral activity.
In one aspect, a method for suppressing BLV-related lymphocyte proliferation is provided. In the method, the proliferation of BLV-infected cells is suppressed by administering an amount of a Shiga-toxin polypeptide having antiviral activity effective to suppress BLV-related lymphocyte proliferation. The administration of the Shiga-toxin polypeptide can prevent or treat the manifestations of BLV infection. In one embodiment, a purified Shiga-toxin polypeptide having antiviral activity is administered. In another embodiment, a naturally occurring microorganism expressing a Shiga-toxin polypeptide having antiviral activity is administered. In a further embodiment, a Shiga-toxin-expressing microorganism that has been modified to eliminate expression of the B subunit of the holotoxin is administered. In yet another embodiment, a microorganism that has been modified to express a Shiga-toxin polypeptide having antiviral activity is administered. In another embodiment, a transgenic plant that has been modified to express a Shiga-toxin polypeptide having antiviral activity is administered.
In another aspect of the invention, compositions for delivering a Shiga-toxin polypeptide are provided. In one embodiment, the

Affiliated with

Also associated with

Rating

Methods and compositions for suppressing bovine leukemia... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for suppressing bovine leukemia..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for suppressing bovine leukemia... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3066728